Ascension Asset Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
$2.1M Sell
6,737
-25
-0.4% -$7.34K 1.1% 28
2024
Q1
$1.92M Buy
+6,762
New +$1.98M 1.04% 34
2023
Q2
$1.48M Buy
+6,662
New +$1.55M 0.9% 41
2022
Q4
$1.79M Hold
6,802
1.29% 32
2022
Q3
$1.53M Hold
6,802
1.2% 35
2022
Q2
$1.66M Buy
+6,802
New +$1.67M 1.22% 34
2021
Q4
$1.52M Sell
6,769
-135
-2% -$28.5K 0.9% 44
2021
Q3
$1.47M Hold
6,904
0.96% 45
2021
Q2
$1.68M Sell
6,904
-91
-1% -$22.4K 1.1% 40
2021
Q1
$1.74M Buy
+6,995
New +$1.67M 1.22% 34
2020
Q4
Sell
-7,270
Closed -$1.85M 36
2020
Q3
$1.85M Buy
+7,270
New +$1.8M 1.48% 24
2020
Q1
$1.46M Hold
7,200
1.52% 25
2019
Q4
$1.74M Hold
7,200
1.5% 28
2019
Q3
$1.39M Sell
7,200
-425
-6% -$81.6K 1.29% 37
2019
Q2
$1.41M Hold
7,625
1.24% 38
2019
Q1
$1.45M Sell
7,625
-75
-1% -$14.3K 1.3% 34
2018
Q4
$1.5M Sell
7,700
-25
-0.3% -$4.88K 1.52% 26
2018
Q3
$1.6M Buy
7,725
+25
+0.3% +$4.93K 1.41% 28
2018
Q2
$1.42M Sell
7,700
-225
-3% -$39.8K 1.3% 36
2018
Q1
$1.35M Hold
7,925
1.23% 36
2017
Q4
$1.38M Buy
+7,925
New +$1.4M 1.26% 37

Other funds holding AMGN

Ascension Asset Management's AMGN Position: Q2 2024 in Review

Ascension Asset Management reduced its Amgen (AMGN) stake by 0.37% in Q2 2024, selling an estimated $7.34K and leaving 6,737 shares worth $2.1M. The position accounts for 1.1% of the portfolio, ranked #28.

Ascension Asset Management first reported a position in AMGN in Q4 2017 and has held it in 21 quarters since. 2,784 funds tracked by Wall St. Rank hold AMGN as of Q2 2024.

  • Ascension Asset Management held 6,737 shares of Amgen worth $2.1M as of Q2 2024.
  • Ascension Asset Management sold 25 Amgen shares in Q2 2024, an estimated $7.34K.
  • Amgen made up 1.1% of Ascension Asset Management's portfolio in Q2 2024, its #28 holding.
  • Ascension Asset Management first reported a position in Amgen in Q4 2017 and has held it in 21 quarters since.
  • 2,784 funds tracked by Wall St. Rank held Amgen as of Q2 2024.

Based on Ascension Asset Management's 13F filing for Q2 2024, filed 16 Aug 2024.